Mirum Pharmaceuticals (Mirum Pharmaceuticals) Change In Receivables : $-30.3 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Mirum Pharmaceuticals Change In Receivables?

Mirum Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2024 was $13.0 Mil. It means Mirum Pharmaceuticals's Accounts Receivable declined by $13.0 Mil from Dec. 2023 to Mar. 2024 .

Mirum Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was $-44.0 Mil. It means Mirum Pharmaceuticals's Accounts Receivable increased by $44.0 Mil from Dec. 2022 to Dec. 2023 .

Mirum Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2024 was $55.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Mirum Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2024 was 72.50.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Mirum Pharmaceuticals's liquidation value for the three months ended in Mar. 2024 was $-62.5 Mil.

Mirum Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Mirum Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirum Pharmaceuticals Change In Receivables Chart

Mirum Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-20.73

-43.97

Mirum Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.67	-10.67	-12.51	-20.13	12.97

Mirum Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.3 Mil.

Mirum Pharmaceuticals (NAS:MIRM) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Mirum Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	54.999	/	69.222	*	91
=	72.50

2. In Ben Graham's calculation of liquidation value, Mirum Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Mirum Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	302.843	-	417.359	+	0.75 * 54.999	+	0.5 * 21.606
=	-62.5

Mirum Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Mirum Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Mirum Pharmaceuticals (Mirum Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (NAS:MIRM) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

MIRM:Mexico 08D:Germany

Address

950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404

Website

https://www.mirumpharma.com

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Executives

Peter Radovich	officer: Chief Operating Officer	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Jolanda Howe	officer: SVP, Global Controller	C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Lara Longpre	officer: Chief Development Officer	C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Pamela Vig	officer: Chief Scientific Officer	C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Christopher Peetz	director, officer: President and CEO	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Patrick J Heron	director, 10 percent owner	550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301
Michael G Grey	director, officer: Executive Chairman	C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Eric Bjerkholt	officer: Chief Financial Officer	132 PURDURE AVENUE, KENGSINGTON CA 94708
Timothy P Walbert	director	1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Lon Cardon	director	C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Niall O'donnell	director	C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Ian Clements	officer: SVP Finance & Communications	C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Edwin Jonathan Tucker	officer: Chief Medical Officer	C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404